Hosam Zaghloul, Doaa A Shahin, Ibrahim El-Dosoky, Mahmoud E El-awady, Fardous F El-Senduny, Nashwa K Abousamra and Farid A Badria
Mansoura University, Egypt
Posters & Accepted Abstracts: J Cancer Sci Ther
Background: Antisense oligonucleotides (ASO) represent an attractive trend in the development of targeted cancer
therapies with more than 90 ASO-based drugs targeting cancer in different phases of clinical trials. Coupling of
ASO to superparamagnetic iron oxide nanoparticles (SPIONs) overcome many challenges related to ASO delivery
including; stabilization in physiological environments, protection from nuclease degradation, enhanced cellular
uptake without using auxiliary reagents and prolonged intracellular half-life.
Aim: To functionalize SPIONs with ASO targeting the mRNA of Cyclin B1, a potential cancer target and to explore
its anticancer activity.
Methods: Four different SPIONs-ASO conjugates termed S-M (1-4) were designated depending on the sequence of
ASO and prepared by crosslinking carboxylated SPIONs to amino labeled ASO. The impact of S-M (1-4) on the level
of Cyclin B1, cell cycle, ROS and viability of the cells were assessed by flowcytometry.
Results: S-M3 and S-M4 reduced the level of Cyclin B1 by 35 and 36%, respectively. In addition, MCF7 cells were
arrested at G2/M phase (60.7%) as a consequence to downregulation of Cyclin B1. S-M (1-4) led to the induction of
ROS formation in comparison to the untreated control cells. Furthermore, S-M (1-4) resulted in an increase in the
percentage of dead cells compared to control ones.
Conclusion: Targeting Cyclin B1 with ASO-coated SPIONs may represent a specific biocompatible anticancer
strategy.
E-mail: hosam_z@yahoo.com
Cancer Science & Therapy received 3968 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 